Introduction
The class of drugs known as phosphodiesterase-5 (PDE-5) inhibitors includes sildenafil citrate (Viagra w , Pfizer), tadalafil (Cialis w , Eli Lilly) and vardenafil hydrochloride trihydrate (Levitra w , Bayer), and is marketed and approved for use in the USA in the treatment of erectile dysfunction (ED). During the last decade, these oral drugs have been the first-line treatment for ED as they are easily administered, relatively non-invasive, reversible and well tolerated. However, taking these drugs can be dangerous to those who suffer from certain comorbid conditions such as hypertension, heart disease or diabetes, or those who take nitrates, a-blockers or blood-thinning medication (1) .
As a result, many men seek alternative medicines, in the form of herbal and dietary supplements, as a therapy for ED with the belief that these products are safe. Studies indicate that these products are often found to contain the active pharmaceutical ingredients (APIs) such as sildenafil, tadalafil or vardenafil (2 -6) or analogs of these approved APIs (5, 7 -27) . Furthermore, products containing multiple PDE-5 inhibitors have been found, both in the literature (5, 10, 18) and in samples analyzed by the US Food and Drug Administration.
Currently, several methods are available to determine a single PDE-5 inhibitor or analog (2, 11, 16, 26, 28 -31) , and some are designed to assay more than one analyte (4 -6, 24, 32 -34) using either high-performance liquid chromatography with ultraviolet detection or liquid chromatography -mass spectrometry (LC -MS). In cases where certain combinations of PDE-5 inhibitors and/or analogs are present in a single matrix, recently up to six in one dietary supplement, it may be necessary to run the sample by more than one method to determine the levels of analytes present. A single method able to analyze samples containing multiple PDE-5 inhibitors, and the large number of analogs detected to date, was desired.
In 
Standard preparation
Stock standards were prepared at concentrations of 0.2 mg/mL as the free base. Serial dilutions of the stock standard, down to 20 mg/mL, were prepared to create a three-point calibration curve. The standards were made and diluted in CH 3 CN : H 2 O (50 : 50, v/v). Multiple analytes may be combined into a single solution or prepared separately.
For determination of analogs for which only a limited amount of standard is available, a single solution of the analyte of interest was prepared for the purpose of retention time comparison. To estimate quantity, a calibration curve was prepared using a standard that most closely resembled the analog in structure, ultraviolet (UV) spectral characteristics, and experimentally determined molar absorptivity. These data, as shown in Figures 1 and 2 and Table I , indicate the successful use of a structurally related compound to estimate content.
Sample preparation
A representative number of dosage units, generally 5 -10 capsules or tablets, were combined to create a composite. When working with a sample that did not have a declared level, a portion equivalent to one-tenth to one-half tablet or capsule content weight was transferred to a suitably sized volumetric flask. Samples having a declared level of API were prepared such that the resulting analyte concentration was 0.1 mg/mL. For both types of samples, the flasks were filled For fortified samples, an additional portion of sample was prepared in the same manner as the initial sample preparation. Prior to adding solvent, the sample was fortified with an amount of appropriate standard equivalent to 50-150% of the amount determined to be present in the sample and thoroughly mixed to combine. If a sufficient quantity of an analog standard was not available, a standard was chosen that most closely resembled the analog. The fortified sample was then prepared as described above. If necessary, the filtrate was diluted further in order for the peak area response to fall within the calibration curve.
Selection of detection wavelength
For the selection of a suitable detection wavelength, standard solutions of 15 PDE-5 inhibitors and analogs were analyzed to determine absorbance. The absorbance spectra were collected using a Hewlett-Packard HP8452A Diode-Array Spectrophotometer (Agilent, Santa Clara, CA, USA). Samples were prepared in solutions of CH 3 region of 280 -300 nm, but they do exhibit absorbance. The region of 285 nm, as opposed to a wavelength in the 215-230 nm range, is selective towards the analytes of interest, and exhibits reduced background absorbance. When necessary, detection at 230 nm allows for increased signal when analyzing low levels of analyte in various samples.
HPLC instrument parameters
Analyses were performed using a Waters 2690 Alliance System with a 996 PDA Detector, Empower Software v.2 from Waters Corporation (Milford, MA, USA) and a Zorbax Eclipse XDB-C8, 150 Â 4.6 mm, 5 mm column from Agilent Technologies (Santa Clara, CA, USA). The mobile phase consisted of a 10 min gradient method using Solvent A, 0.1% TFA in H 2 O, and Solvent B, 0.1% TFA in CH 3 CN. The gradient was performed as follows: 0 min, 25% B; 0 -7 min, linear to 50% B and 3 min, hold at 50% B. The column was equilibrated at 25% B for 5 min between runs. The flow rate was 1 mL/min, the injection volume was 10 mL and the column temperature was ambient. The detection wavelength was 285 nm, with optional dual detection at 230 nm or online spectral collection from 210 to 400 nm as necessary. If a reference wavelength is used, care in its selection should be taken, as xanthoanthrafil and the thione analogs demonstrate strong absorbance at higher wavelengths ( Figure 2 ).
Method validation
The linearity and dynamic range of the method were evaluated using a series of standard solutions. Multiple injections of a wide range of concentrations of vardenafil, sildenafil, tadalafil and the 12 analogs were used to construct calibration curves, and the correlation coefficient, y-intercept and slope were calculated. The average retention time and relative retention time to sildenafil were also determined.
Injection precision, limit of detection (LOD) and limit of quantitation (LOQ) for each analyte were determined. One of the system suitability parameters that must be met in a typical United States Pharmacopeia monograph concerns the relative standard deviation (RSD) for replicate injections. To mimic that requirement, a mid-level standard was injected five times. In order to determine LOD and LOQ, a low-level standard was injected seven times, and the standard deviation (SD) was determined. The LOD was defined as three times the SD, and the LOQ as ten times the SD, for each analyte.
Method accuracy and precision were assessed using dosage forms of Levitra w , Viagra w and Cialis w . Four preparations of each dosage form were evaluated using the gradient method, and the assay values were compared with those obtained using the manufacturer's methods for vardenafil, sildenafil and tadalafil. Additional method accuracy data from various dosage forms were determined by comparing assay values to those obtained using the manufacturer's methods.
Ruggedness of the method was determined using Waters, Dionex and Agilent HPLC systems, various C8 columns and multiple analysts. Composites of Levitra w , Viagra w and Cialis w were analyzed, as were three dietary supplement capsule composites that were fortified with homosildenafil, hydroxyhomosildenafil or sulfoaildenafil.
Results

Specificity
The relative retention times for 15 PDE-5 inhibitors and analogs were determined. Initially, 14 of the analytes were combined into a single mixed standard and analyzed. Table II lists the relative retention time, with respect to sildenafil, for the compounds evaluated. This includes the more recently obtained xanthoanthrafil, which was analyzed individually for inclusion with the mixed standard results.
Chromatographic results for the dietary supplement matrix used in the preparation of the homosildenafil, sulfoaildenafil and hydroxyhomosildenafil samples for determination of method ruggedness showed no peaks in the retention time range of the PDE-5 inhibitors and analogs.
Additionally, specificity was also demonstrated by the lack of interference from compounds detected in conjunction with PDE-5 inhibitors and analogs, such as caffeine, amino acids, fatty acids, sugar alcohols, synephrine and menthol. Figure 3 . Determined experimentally, see Figure 2 .
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Chromatography, linearity, dynamic range, LOD and LOQ Over an extended period of time, multiple concentrations of standards of vardenafil, sildenafil, tadalafil and the 12 analogs were analyzed in duplicate, at minimum, using a single HPLC column. The RSD values for intraday injections are typically ,1.0%.
The RSD values for interday analyses are typically ,2.0%, indicating excellent system stability. Calibration curves for the 15 analytes were constructed to determine linearity. Concentrations ranged from 1 to 10 mg/mL for the low standard and 200 to 400 mg/mL for the high standard, and each curve covered at least two orders of magnitude. At least three concentrations of standards were used to create the calibration curve, and each standard was injected a minimum of three times. The correlation coefficient for each curve was calculated to be 0.999 or better. The RSD for injection precision for five injections of a 0.1 mg/mL solution was 0.4% or less for all of the analytes. To determine LOD and LOQ, a 1 mg/mL solution of each of the analytes was injected seven times. The calculated LOD was 0.2 mg/mL or less, and the LOQ was 0.5 mg/mL or less.
Accuracy and precision
Duplicate preparations of various dosage forms were evaluated by comparing assay values to those obtained using the manufacturer's methods, as shown in Table III . For sildenafil concentrations ranging from 15 to 130 mg per dosage unit, the result from the gradient method was within 94% of the value obtained from the monograph (35) . For tadalafil concentrations ranging from 4.5 to 20 mg per dosage unit, the result was within 90% of the manufacturer's method.
Additionally, the gradient method was applied to the three approved dosage forms, and the results were compared with the declared milligram per tablet level. Composites of the approved products were prepared, and four preparations of each composite were analyzed. For Levitra w 20 mg tablets, the average assay value was 20.4 + 0.5 mg (102% declared). For Cialis w 10 mg tablets, the average value was 9.8 + 0.2 mg (98% declared) and for Viagra w 100 mg tablets, the average value was 100 + 1 mg (100% declared). Table IV shows recovery data for samples fortified with various levels of sildenafil, tadalafil and sulfoaildenafil. Recoveries ranged from 87 to 104% for sildenafil, 87 to 107% for tadalafil and 95 to 104% for sulfoaildenafil.
Ruggedness
To evaluate method ruggedness, composites of the three approved products and three dietary supplement capsule composites, each containing an analog, were analyzed using separate HPLC systems and multiple analysts, as outlined in Table V . For Viagra w 50 mg tablets, the range in assay values was 47-51 mg. For Cialis w 20 mg tablets, the range was 19 -20 mg and for Levitra w 10 mg tablets, the range was 9.3 -9.9 mg. For a dietary supplement prepared to contain 72 mg homosildenafil per capsule, the range was 71 -75 mg. For a prepared 43 mg sulfoaildenafil per capsule composite, the range was 44-45 mg, and for a prepared 59 mg hydroxyhomosildenafil per capsule composite, the range was 58 -65 mg. It was also demonstrated that the assay values at 230 nm were comparable with the values for 285 nm.
Discussion
Prior to the development of this method, the determination of sildenafil, tadalafil or vardenafil was performed using individual methods. Sildenafil was determined using the Pharmaceutical Forum monograph for "Sildenafil Tablets" (35) . Tadalafil and vardenafil were determined using proprietary methods provided by the manufacturers. Because these methods required the preparation of unique mobile phases and sample diluents, and utilized different chromatographic columns and system parameters, it was problematic to analyze samples containing more than one PDE-5 inhibitor, particularly in cases where the amount of sample was limited.
Before the samples were assayed, they were analyzed using LC -MS for identification purposes (3) . Using the chromatography parameters of the LC -MS method as a guide, it was determined that a similar method could be used for the quantification of PDE-5 inhibitors and analogs. The resulting gradient program can separate 14 of the 15 PDE-5 inhibitors and analogs investigated within 10 min, as shown in Figure 3 . Tadalafil and pseudovardenafil cannot be separated chromatographically using these parameters, but they can be distinguished by their UV spectra. If complete separation is necessary, the Sildenafil Tablet composite  52  50  Tablet composite  92  93  Tablet composite  59  59  Tablet composite  97  99  Tablet composite  74  73  Tablet composite  75  79  Capsule composite  60  61  Capsule composite  81  77  Tablet composite  87  87  Tablet composite  53  52  Tablet composite  96  95  Tablet composite  92  90  Tablet composite  96  96  Tablet composite  130  130  Tablet composite  16  16  Tablet composite  15  15  Tadalafil  Tablet composite  20  18  Tablet composite  73  71  Tablet composite  17  17  Tablet composite  20  19  Tablet composite  19  18  Tablet composite  19  19  Tablet composite  19  20  Tablet composite  20  20  Tablet gradient can be extended to 18 min. This extended gradient method also provides greater resolution for the pairs of vardenafil and hydroxyacetildenafil, homosildenafil and dimethylsildenafil and thiohomosildenafil and sulfoaildenafil. In practice, the vast majority of samples analyzed do not contain the closely retained pairs, so the shorter gradient method is sufficient and generally recommended. The PDE-5 inhibitors and analogs analyzed were grouped into six distinct classes based on their UV spectra, as shown in Figure 2 . Using these classes, suitable standards for estimation, when the specific analyte is not available or is cost prohibitive for infrequent analysis, can be selected more easily. Additionally, if a The values for average, SD, RSD, 95% confidence interval (CI) and percent declared were calculated using all analysts' preparations.
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Conclusion
This method provides separation of 14 PDE-5 inhibitors and analogs in a variety of forms, including tablets, capsules, bulk powders, troches and liquids, in 10 min. It is linear over a wide range of concentrations, sensitive to trace levels, accurate in dosage forms as well as supplements and rugged across analysts and instruments. Additionally, by expanding the gradient method to an 18-min run-time, all 15 compounds can be resolved, offering the flexibility needed to separate and analyze new analogs as they are encountered. Additionally, UV data presented indicate that PDE-5 inhibitors with similar structures have similar spectra and similar molar absorptivities. This proved useful in the latest characterization of two new tadalafil analogs, 2-hydroxypropylnortadalafil and n-butylnortadalafil (36), as they have spectra similar to tadalafil. As the work in this field of study continues, it may be difficult to maintain an up-to-date collection of each standard needed to perform quantitative analysis and the ability to use a spectrally related compound to provide estimated levels is helpful in cases where the procurement of a standard is difficult, time consuming or cost prohibitive. 
